Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-In-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-Line Safety and Pharmacokinetic Findings.
Intra-Cellular Therapies, Inc. ("ITI") today announced the completion of a Phase I single rising dose study of its phosphodiesterase 1 (PDE1) inhibitor, ITI-214. ITI-214, a novel, first-in-class selective PDE1 inhibitor, was discovered by ITI and is in development under an exclusive collaboration with Takeda Pharmaceutical Company Limited for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).
View HTML
Toggle Summary Intra-Cellular Therapies and Takeda enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States. ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Positive Results With Iti-002 in Pre-Clinical Models of Parkinson's Disease.
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
View HTML
Toggle Summary Intra-Cellular Therapies Announces the Successful Completion of a Phase IB/II Study Of ITI-007 In Patients with Schizophrenia. View HTML
Toggle Summary Intra-Cellular Therapies Announces the Results of a Phase I Pet Study For ITI-007 for the Treatment of Schizophrenia and other Psychiatric Disorders.
Key Targets are Critical to Drug Treatment of Neuropsychiatric and Related Disorders
View HTML
Toggle Summary Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial With ITI-007 in Patients with Sleep Maintenance Insomnia. View HTML
Toggle Summary Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial With Iti-007 in Patients With Sleep Maintenance Insomnia
"TRIAL CONCLUDED EARLY DUE TO ACHIEVEMENT OF STATISTICAL SIGNIFICANCE DEMONSTRATED AT THE PRIMARY ENDPOINT"
View HTML
Toggle Summary Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007 View HTML
Toggle Summary Intra-Cellular Therapies Presents Data on its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders. View HTML
Toggle Summary Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia. View HTML
Toggle Summary Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs. View HTML
Toggle Summary Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD). View HTML
Toggle Summary Intra-Cellular Therapies Initiates Phase I Clinical Program for Schizophrenia and Sleep Maintenance Disorders.
ITI-007 - A Novel, First-in-Class Dual 5HT2A Receptor Antagonist/Dopamine Phosphoprotein Modulator (DPPM) for Schizophrenia and ITI-722- A 5HT2A Receptor Antagonist for Sleep Maintenance Disorders
View HTML
Toggle Summary Intra-Cellular Therapies, Inc. Receives Exclusive License for Central Nervous System Compounds from Bristol-Myers Squibb Company. View HTML